Navigation Links
GeoVax to Exhibit at the 2009 BIO International Convention
Date:5/11/2009

Dr. Harriet Robinson to Host HIV Vaccine Panel Discussion

ATLANTA, May 11 /PRNewswire-FirstCall/ --

    WHAT:    GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based,
             publicly traded biopharmaceutical company developing human
             vaccines for diseases caused by HIV-1 (Human Immunodeficiency
             Virus) and other infectious agents to share their strategy for
             the future and plans to expand preventative trials, currently in
             Phase 2a, to proof-of-concept trials in 'at risk' humans and
             move therapeutic trials from non-human primate models to HIV-1
             virus infected individuals.

             Dr. Harriet Robinson to moderate "HIV/AIDS Vaccines: Preventative
             and Therapeutic Approaches to a Global Pandemic"

    WHERE:   2009 BIO International Convention
             Georgia Pavilion (Booth #2817)
             Georgia World Congress Center
             Atlanta, GA

    WHEN:    May 18-21, 2009
             "HIV/AIDS Vaccines: Preventative and Therapeutic Approaches to a
             Global Pandemic" Thursday, May 21, 10-11 a.m., Room B309

    WHO:     Robert McNally, Ph.D., chief executive officer and president
             Mark Reynolds, chief financial officer
             Harriet Robinson, PhD, vice president of research and development
             and developer of the GeoVax vaccine

    WHY:     HIV Vaccine Awareness Day coincides with the opening of the
             conference on May 18, and Sir Elton John delivering a keynote
             address to include how biotechnology is influencing treatment and
             prevention of the diseases.  GeoVax is looking forward to sharing
             with interested partners, investors and media its progress in
             clinical trials during the last six months and its strategy for
             the future.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. GeoVax Labs, Inc. Announces First Quarter Financial Results
2. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
3. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
4. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
5. GeoVax to Present at the BIO CEO & Investor Conference 2009
6. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Presents Data at AIDS Vaccine 2008 Conference
9. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
10. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
11. GeoVax Further Strengthens Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , ... March 21, 2017 , ... Okyanos Cell Therapy ... as part of their live events series, “Stem Cell Therapy: The Next Phase in ... under the 2013 Stem Cell Research and Therapy Act, Okyanos maintains a ...
(Date:3/22/2017)... ... March 21, 2017 , ... Benchworks CEO Thad L. Bench ... on March 23-24 in San Diego. The event is a gathering of executive ... , Benchworks Vice President Christian Meyer will also participate in the forum. Participants will ...
(Date:3/22/2017)... York, NY (PRWEB) , ... March 21, 2017 , ... ... Officer Summit (CMO Summit) to be held on May 10-11, 2017, at the ... in the country specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. , ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... Functional near-infrared ... oxygenation, is being explored as a way to track the brain’s response to acute ... pain activation by cold pressor test ,” published today in the journal Neurophotonics ...
Breaking Biology Technology:
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... 28, 2017 News solutions for biometrics, bag ... ... from 14 to 16 March, Materna will present its complete ... seamless travel is a real benefit for passengers. To accelerate ... their passenger touch point solutions to take passengers through the complete ...
(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
Breaking Biology News(10 mins):